A study by the University of Barcelona has discovered why the two main types of lung cancer—adenocarcinoma of the lung and ...
Morning Overview on MSN
A bispecific antibody beat a standard immunotherapy regimen head-to-head in squamous lung cancer at ASCO 2026
A bispecific antibody that simultaneously targets PD-1 and VEGF extended overall survival by more than four months compared ...
A study by the University of Barcelona has discovered why the two main types of lung cancer - adenocarcinoma of the lung and ...
Squamous cell carcinoma of the lung is linked to smoking and requires early detection and accurate staging for effective treatment. Diagnosis involves imaging and biopsy, with the TNM system used to ...
Significant reductions seen in non-small cell lung cancer, breast cancer, colorectal cancer, and hepatocellular carcinoma.
Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...
At the 2026 ASCO Annual Meeting, Ajaz Khan, MD, of City of Hope, highlighted several significant developments across breast ...
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...
Bizengri received accelerated approval for NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma, showing ORRs of 33% and 40%, respectively, with varying DORs. Imfinzi significantly improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results